Complement 1 Secures $16 Million in Seed Funding to Revolutionize Cancer Care
[City, Date] — Complement 1, a pioneering health tech company dedicated to transforming cancer treatment through personalized lifestyle medicine, has successfully closed an oversubscribed $16 million seed funding round, led by Owl Ventures and Blume Ventures, alongside several notable angel investors.
Emerging from stealth mode, Complement 1 has introduced the first tech-enabled lifestyle modification platform specifically designed for cancer patients and high-risk individuals. The platform features dedicated CoActive Coaches who provide personalized, daily guidance and education tailored to each patient’s unique cancer type and treatment stage. Powered by an evidence-backed, clinically validated rule engine, the program leverages guidelines curated by leading oncologists and the American Institute for Cancer Research, facilitating a highly customized care pathway.
"Integrating healthy lifestyle changes into cancer care can be transformative," states CEO Karan Bajaj. "Lifestyle change is one of the most powerful yet underused tools in cancer care. We’ve cracked the code on daily engagement with personalized, compassionate coaching.” Clinical trial results indicate that Complement 1 users experience 37% fewer treatment side effects, 18% less pain, and improved sleep quality while maintaining a 90% adherence rate.
The new funding will enable Complement 1 to expand its coaching operations across the U.S., enhance its AI-driven personalization engine, and forge partnerships with cancer centers and health providers. "This funding will help us scale our impact through a hybrid approach that combines technological infrastructure with high-touch delivery," said Trupti Mukker, Co-founder and COO.
As cancer incidence rates rise, Complement 1 aims to bridge critical gaps in oncology care, offering patients and healthcare systems a revolutionary model for improving cancer outcomes.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
